Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12475924 | 1.00 | HTR2A (0.45) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12476207 | 0.87 | ALDH1A1 (0.47) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12475982 | 0.87 | ALDH1A1 (0.47) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12476680 | 0.81 | HTR2A (0.45) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL19209361 | 0.80 | HTR2A (0.55) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL15676014 | 0.79 | HTR2A (0.55) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12476676 | 0.77 | SSTR3 (0.49) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12477118 | 0.76 | HTR2A (0.58) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL6594172 | 0.73 | HTR2A (0.74) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL16599526 | 0.72 | HTR2A (0.54) | HTR2AGAAALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968647-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-3147367-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| EP-2658981-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2658982-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-9301990-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9198947-B2 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2658982-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| EP-2658981-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012089602-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012089352-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | SNRPE, PHAX, SNRPA | HTR2A 4648/4885GAA 145/4885ALDH1A1 3291/4885 |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | SNRPE, PHAX, SNRPA | HTR2A 4461/4885GAA 516/4885ALDH1A1 3508/4885 |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | SNRPE, PHAX, SNRPA | HTR2A 4648/4885GAA 145/4885ALDH1A1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.